Blackstone Amends Stake in Autolus Therapeutics

TL;DR

Blackstone just updated their Autolus Therapeutics stake. Watch this space.

AI Summary

On May 21, 2024, Blackstone Inc. filed an SC 13D/A amendment regarding Autolus Therapeutics plc. This filing indicates a change in beneficial ownership, with Blackstone entities now holding a significant stake in the company. The specific percentage and number of shares are detailed within the filing.

Why It Matters

This filing signals a potential shift in control or influence for Autolus Therapeutics, as a major investment firm like Blackstone adjusts its holdings. Investors will monitor future actions for potential strategic implications.

Risk Assessment

Risk Level: medium — Changes in major shareholder positions can indicate shifts in company strategy or financial health, requiring careful investor observation.

Key Players & Entities

• Blackstone Inc. (company) — Filing entity
• Autolus Therapeutics plc (company) — Subject company
• Stephen A. Schwarzman (person) — Group member of Blackstone

FAQ

Key Financial Figures

• $0.000042 — nting one ordinary share, nominal value $0.000042 per share (Title of Class of Securiti

Filing Documents

• d841342dsc13da.htm (SC 13D/A) — 138KB
• 0001193125-24-143963.txt ( ) — 140KB

From the Filing

SC 13D/A 1 d841342dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 ** (CUSIP Number) John G. Finley Blackstone Inc. 345 Park Avenue New York, New York 10154 (212) 583-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 17, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. ** There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol AUTL. Each American Depositary Share represents the right to receive one ordinary share. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 05280R100 1 NAMES OF REPORTING PERSONS BXLS V Autobahn L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) OO 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 23,750,917* 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 23,750,917* 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 23,750,917* 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.8%** 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN * Includes 3,265,306 shares underlying warrants to purchase ADSs that are exercisable within 60 days. ** Percentage is calculated in accordance with Rule 13d-3 of the Securities and Exchange Act of 1934, as amended (the Exchange Act). 2 CUSIP No. 05280R100 1 NAMES OF REPORTING PERSONS Blackstone Life Sciences Associates V (CYM) L.L.C. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) OO 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 23,750,917* 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 23,750,917* 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 23,750,917* 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.8%** 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO * Includes 3,265,306 shares underlying warrants to purchase ADSs that are exercisable within 60 days. ** Percentage is calculated in accordance with Rule 13d-3 of the Exchange Act. 3 CUSIP No. 05280R100 1 NAMES OF REPORTING PERSONS Blackstone Clarus GP L.L.C. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) OO 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 23,750,917* 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 23,750,917* 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 23,750,917* 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF C

View Full Filing

View this SC 13D/A filing on SEC EDGAR